Allergan Rejects Valeant Again

Jun 10 2014 | 12:00pm ET

Valeant Pharmaceuticals International’s $53 billion offer for Allergan Inc. is still not rich enough for the latter.

Valeant, which is working with Pershing Square Capital Management on the bid, increased the offer twice late last month. But Allergan, which has said it prefers to remain independent, isn’t budging.

“We do not believe your latest proposal offers sufficient or certain value to warrant discussions between Allergan and Valeant,” Allergan CEO David Pyott wrote to his counterpart at Valeant, Michael Pearson.

That is not likely to sit well with Pershing Square’s William Ackman, Allergan’s largest shareholder, who has championed a deal and insisted that Allergan hold talks with Valeant. This week, Ackman said he had the support of a number of large Allergan investors for a deal at $180 per share, roughly the value of Valeant’s latest bid.

Ackman is also preparing a proxy fight to oust a majority of Allergan’s board later this year. The Botox-maker said the board’s vote against Valeant’s most recent offer was unanimous.

Allergan has blasted Valeant as a serial acquirer whose strategy is unsustainable. Pyott wrote that the latest proposal both “substantially undervalues” his company and “creates significant risks and uncertainties.”


In Depth

Steinbrugge: Top 10 Hedge Fund Industry Trends for 2017

Jan 3 2017 | 9:03pm ET

Each year, Agecroft Partners' Don Steinbrugge predicts the top hedge fund industry...

Lifestyle

'Tis the Season: Wall Street Holiday Parties Back In Fashion

Dec 22 2016 | 9:23pm ET

Spending on Wall Street holiday parties has largely returned to pre-2008 levels...

Guest Contributor

DarcMatter: The Top Trends in Alternative Investments for 2017

Jan 13 2017 | 8:22pm ET

The $7 trillion alternative investments industry is poised for continued growth...

 

From the current issue of

The U.S. Commodity Futures Trading Commission (CFTC) ordered The Goldman Sachs Group Inc., and Goldman, Sachs & Co. to pay a $120 million penalty for attempted manipulation and false reporting of ISDAFIX Benchmark Rates, a global benchmark for interest rate products.